BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 24606526)

  • 1. Leukaemic cells from chronic lymphocytic leukaemia patients undergo apoptosis following microtubule depolymerization and Lyn inhibition by nocodazole.
    Frezzato F; Trimarco V; Martini V; Gattazzo C; Ave E; Visentin A; Cabrelle A; Olivieri V; Zambello R; Facco M; Zonta F; Cristiani A; Brunati AM; Moro S; Semenzato G; Trentin L
    Br J Haematol; 2014 Jun; 165(5):659-72. PubMed ID: 24606526
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nocodazole, a microtubule de-polymerising agent, induces apoptosis of chronic lymphocytic leukaemia cells associated with changes in Bcl-2 phosphorylation and expression.
    Beswick RW; Ambrose HE; Wagner SD
    Leuk Res; 2006 Apr; 30(4):427-36. PubMed ID: 16162358
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The novel tubulin-targeting agent pyrrolo-1,5-benzoxazepine-15 induces apoptosis in poor prognostic subgroups of chronic lymphocytic leukemia.
    McElligott AM; Maginn EN; Greene LM; McGuckin S; Hayat A; Browne PV; Butini S; Campiani G; Catherwood MA; Vandenberghe E; Williams DC; Zisterer DM; Lawler M
    Cancer Res; 2009 Nov; 69(21):8366-75. PubMed ID: 19826055
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chronic lymphocytic leukemia B cells contain anomalous Lyn tyrosine kinase, a putative contribution to defective apoptosis.
    Contri A; Brunati AM; Trentin L; Cabrelle A; Miorin M; Cesaro L; Pinna LA; Zambello R; Semenzato G; Donella-Deana A
    J Clin Invest; 2005 Feb; 115(2):369-78. PubMed ID: 15650771
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Benzylamide sulindac analogues induce changes in cell shape, loss of microtubules and G(2)-M arrest in a chronic lymphocytic leukemia (CLL) cell line and apoptosis in primary CLL cells.
    Moon EY; Lerner A
    Cancer Res; 2002 Oct; 62(20):5711-9. PubMed ID: 12384529
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lyn-mediated SHP-1 recruitment to CD5 contributes to resistance to apoptosis of B-cell chronic lymphocytic leukemia cells.
    Tibaldi E; Brunati AM; Zonta F; Frezzato F; Gattazzo C; Zambello R; Gringeri E; Semenzato G; Pagano MA; Trentin L
    Leukemia; 2011 Nov; 25(11):1768-81. PubMed ID: 21701493
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cortactin, a Lyn substrate, is a checkpoint molecule at the intersection of BCR and CXCR4 signalling pathway in chronic lymphocytic leukaemia cells.
    Martini V; Gattazzo C; Frezzato F; Trimarco V; Pizzi M; Chiodin G; Severin F; Scomazzon E; Guzzardo V; Saraggi D; Raggi F; Martinello L; Facco M; Visentin A; Piazza F; Brunati AM; Semenzato G; Trentin L
    Br J Haematol; 2017 Jul; 178(1):81-93. PubMed ID: 28419476
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patients with chronic lymphocytic leukaemia (CLL) differ in the pattern of CTLA-4 expression on CLL cells: the possible implications for immunotherapy with CTLA-4 blocking antibody.
    Ciszak L; Frydecka I; Wolowiec D; Szteblich A; Kosmaczewska A
    Tumour Biol; 2016 Mar; 37(3):4143-57. PubMed ID: 26490985
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rituximab and 17-allylamino-17-demethoxygeldanamycin induce synergistic apoptosis in B-cell chronic lymphocytic leukaemia.
    Johnson AJ; Wagner AJ; Cheney CM; Smith LL; Lucas DM; Guster SK; Grever MR; Lin TS; Byrd JC
    Br J Haematol; 2007 Dec; 139(5):837-44. PubMed ID: 17949452
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting lipid metabolism by the lipoprotein lipase inhibitor orlistat results in apoptosis of B-cell chronic lymphocytic leukemia cells.
    Pallasch CP; Schwamb J; Königs S; Schulz A; Debey S; Kofler D; Schultze JL; Hallek M; Ultsch A; Wendtner CM
    Leukemia; 2008 Mar; 22(3):585-92. PubMed ID: 18079738
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sorafenib induces cell death in chronic lymphocytic leukemia by translational downregulation of Mcl-1.
    Huber S; Oelsner M; Decker T; zum Büschenfelde CM; Wagner M; Lutzny G; Kuhnt T; Schmidt B; Oostendorp RA; Peschel C; Ringshausen I
    Leukemia; 2011 May; 25(5):838-47. PubMed ID: 21293487
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological inhibitors of NF-kappaB accelerate apoptosis in chronic lymphocytic leukaemia cells.
    Pickering BM; de Mel S; Lee M; Howell M; Habens F; Dallman CL; Neville LA; Potter KN; Mann J; Mann DA; Johnson PW; Stevenson FK; Packham G
    Oncogene; 2007 Feb; 26(8):1166-77. PubMed ID: 16924235
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ABT-737 resistance in B-cells isolated from chronic lymphocytic leukemia patients and leukemia cell lines is overcome by the pleiotropic kinase inhibitor quercetin through Mcl-1 down-regulation.
    Russo M; Spagnuolo C; Volpe S; Tedesco I; Bilotto S; Russo GL
    Biochem Pharmacol; 2013 Apr; 85(7):927-36. PubMed ID: 23353698
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Valproic acid induces apoptosis in chronic lymphocytic leukemia cells through activation of the death receptor pathway and potentiates TRAIL response.
    Lagneaux L; Gillet N; Stamatopoulos B; Delforge A; Dejeneffe M; Massy M; Meuleman N; Kentos A; Martiat P; Willems L; Bron D
    Exp Hematol; 2007 Oct; 35(10):1527-37. PubMed ID: 17697742
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel X-linked inhibitor of apoptosis inhibiting compound as sensitizer for TRAIL-mediated apoptosis in chronic lymphocytic leukaemia with poor prognosis.
    Frenzel LP; Patz M; Pallasch CP; Brinker R; Claasen J; Schulz A; Hallek M; Kashkar H; Wendtner CM
    Br J Haematol; 2011 Jan; 152(2):191-200. PubMed ID: 21091905
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The novel receptor tyrosine kinase Axl is constitutively active in B-cell chronic lymphocytic leukemia and acts as a docking site of nonreceptor kinases: implications for therapy.
    Ghosh AK; Secreto C; Boysen J; Sassoon T; Shanafelt TD; Mukhopadhyay D; Kay NE
    Blood; 2011 Feb; 117(6):1928-37. PubMed ID: 21135257
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the in vitro effects of the anti-CD20 antibodies rituximab and GA101 on chronic lymphocytic leukaemia cells.
    Patz M; Isaeva P; Forcob N; Müller B; Frenzel LP; Wendtner CM; Klein C; Umana P; Hallek M; Krause G
    Br J Haematol; 2011 Feb; 152(3):295-306. PubMed ID: 21155758
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bcl-2 and bax expression and chlorambucil-induced apoptosis in the T-cells and leukaemic B-cells of untreated B-cell chronic lymphocytic leukaemia patients.
    Thomas A; Pepper C; Hoy T; Bentley P
    Leuk Res; 2000 Oct; 24(10):813-21. PubMed ID: 10996199
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Microenvironment-induced PIM kinases promote CXCR4-triggered mTOR pathway required for chronic lymphocytic leukaemia cell migration.
    Białopiotrowicz E; Górniak P; Noyszewska-Kania M; Puła B; Makuch-Łasica H; Nowak G; Bluszcz A; Szydłowski M; Jabłonska E; Piechna K; Sewastianik T; Polak A; Lech-Marańda E; Budziszewska BK; Wasylecka-Juszczyńska M; Borg K; Warzocha K; Czardybon W; Gałęzowski M; Windak R; Brzózka K; Juszczyński P
    J Cell Mol Med; 2018 Jul; 22(7):3548-3559. PubMed ID: 29665227
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bone marrow stromal mesenchymal cells induce down regulation of CD20 expression on B-CLL: implications for rituximab resistance in CLL.
    Marquez ME; Hernández-Uzcátegui O; Cornejo A; Vargas P; Da Costa O
    Br J Haematol; 2015 Apr; 169(2):211-8. PubMed ID: 25612644
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.